Dr. Reddy's Laboratories/$RDY

1D1W1MYTD1Y5YMAX

About Dr. Reddy's Laboratories

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Ticker
$RDY
Sector
Health
Primary listing
NYSE
Employees
27,527
Headquarters
Hyderabad, India
Website
www.drreddys.com

RDY Metrics

BasicAdvanced
$10B
28.75
$0.41
0.26
$0.06
0.54%

What the Analysts think about RDY

Analyst ratings (Buy, Hold, Sell) for Dr. Reddy's Laboratories stock.
Analyst projections of the future price of Dr. Reddy's Laboratories stock.

Bulls say / Bears say

Domestic branded and emerging market revenues in India rose 16.76% YoY to Rs 1,717.7 crore in Q1 FY27, outperforming the Indian Pharmaceutical Market’s MAT growth of 13.5%. (Business Standard; Earningscalls.dev)
Commercialized complex generics such as bosutinib and nintedanib in Q1 FY27, bolstering its high-value portfolio with first-to-market exclusivity on bosutinib’s 400 mg launch. (SEC transcript)
Maintains a substantial pipeline with 77 generic filings pending U.S. FDA approval as of March 31, 2026, underpinning future revenue catalysts. (SEC 20-F)
Revenue from operations declined 5.55% YoY to Rs 8,070.5 crore in Q1 FY27, reflecting lower lenalidomide sales and semaglutide API disruptions. (Business Standard; SEC transcript)
Global Generics gross margin narrowed to 51.6% from 60.9% YoY, and EBITDA margin fell to 12.5%, underscoring intensified pricing pressures and higher API-related costs. (Financial Filings; SEC transcript)
Warned that semaglutide supply disruptions could continue to weigh on product availability across global markets as it pursues approvals in Brazil, Turkey, and Mexico. (Reuters via MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.

RDY Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

RDY Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

RDY News

AllArticlesVideos

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Business Wire4 weeks ago

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Business Wire1 month ago

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Business Wire1 month ago

Funds containing RDY

AllEURGBP
Funds
Fund name
Fund size
$RDY weighting
Invesco FTSE All-World€FWIA
€4B0.08%
Invesco FTSE All-World£FWRG
£3.4B0.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.